The Prognostic Effect of Statin Use on Urologic Cancers An Updated Meta-Analysis of 35 Observational Studies

doi:10.1097/MD.0000000000001523

CORC > 兰州大学 > 兰州大学 > 第二临床医学院 > 期刊论文

	The Prognostic Effect of Statin Use on Urologic Cancers An Updated Meta-Analysis of 35 Observational Studies
	Luo, Y; She, DL; Xiong, H; Fu, SJ; Yang, L; Yang, L (reprint author), Lanzhou Univ, Hosp 2, Dept Urol, Lanzhou 730000, Peoples R China.
刊名	MEDICINE
	2015-09
卷号	94 期号:36
ISSN号	0025-7974
DOI	10.1097/MD.0000000000001523
文献子类	Review
英文摘要	Recent studies suggest that statin may benefit cancer prognosis, especially through its radiosensitization effect. But controversy exists in other studies. Hence, we performed a meta-analysis of results from 35 studies to evaluate the effect of statin use on urologic cancers.We conducted computerized search from PubMed, Embase, and ISI Web of Knowledge through May 2015, screened the retrieved references, and collected and evaluated relevant information. We extracted and synthesized corresponding hazard ratios (HR) and confidence interval (CI) by using Review Manager 5.3 and STATA 13. This review was registered at PROSPERO with registration No. CRD42015020171.We selected total 35 retrospective studies and conducted a meta-analysis of results from these studies. The pooled results suggested no benefit of statin use to bladder cancer and renal cell carcinoma, except overall survival [HR=0.81, 95% CI: 0.69-0.96]. However, significant improvement of prostate cancer prognosis including overall survival [HR=0.82, 95% CI: 0.70-0.97] and cancer-specific survival [HR=0.70, 95% CI: 0.59-0.83] was indicated, but not including tumor progression [HR=0.84, 95% CI: 0.62-1.14]. Statin use improved biochemical recurrence of prostate cancer in radiotherapy patients [HR=0.68, 95% CI: 0.54-0.85] but not in radical prostatectomy patients [HR=0.97, 95% CI: 0.82-1.15].Current evidence suggests no benefit of statin use to bladder cancer and renal cell carcinoma, except in overall survival. While statin use benefited prostate cancer patients in overall survival, cancer-specific survival but not in tumor progression; it also improved biochemical recurrence in radiotherapy patients but not in radical patients. To verify these results, randomized controlled trials are necessary.
学科主题	General & Internal Medicine
出版地	PHILADELPHIA
语种	英语
WOS记录号	WOS:000369531900042
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/179395]
专题	第二临床医学院_期刊论文
通讯作者	Yang, L (reprint author), Lanzhou Univ, Hosp 2, Dept Urol, Lanzhou 730000, Peoples R China.
推荐引用方式 GB/T 7714	Luo, Y,She, DL,Xiong, H,et al. The Prognostic Effect of Statin Use on Urologic Cancers An Updated Meta-Analysis of 35 Observational Studies[J]. MEDICINE,2015,94(36).
APA	Luo, Y,She, DL,Xiong, H,Fu, SJ,Yang, L,&Yang, L .(2015).The Prognostic Effect of Statin Use on Urologic Cancers An Updated Meta-Analysis of 35 Observational Studies.MEDICINE,94(36).
MLA	Luo, Y,et al."The Prognostic Effect of Statin Use on Urologic Cancers An Updated Meta-Analysis of 35 Observational Studies".MEDICINE 94.36(2015).